fbpx

molecules of the month

“Compound 4f”

oral, brain-penetrant, reversible MAGL inh.

in vivo PK/PD in CNS (0.3-10 mpk PO)

from HTS and SBDD

Journal of Medicinal Chemistry

Takeda, Fujisawa, Japan

Compound 4f
1 min read

The Takeda MAGL inhibitor, “compound 4f”, was selected by reviewer Joachim Rudolph. “MAGL (monoacylglycerol lipase) is implicated in neuroinflammation, and inhibitors of this enzyme are of interest as therapeutics in neurodegenerative and other neurological diseases. Most of the advanced compounds, including the clinically evaluated ABX-1431, are irreversible inhibitors, but chronic blockade has been found to lead to undesirable desensitization. There is therefore a need for potent, selective reversible inhibitors of MAGL to assess their clinical viability as an alternative to irreversible inhibitors. This work by Takeda scientists reports new potent reversible MAGL inhibitors with good in vivo PK and PD profiles. The chemical structure of the lead 4f and related compounds also use interesting cyclobutyl/azetidine spiro scaffolds.” The molecule started from an…


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: